Barclays
IDXG

Barclays’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Barclays’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Hold
0
– – – 7484
2018
Q1 		– Hold
0
– – – 7511
2013
Q3 		– Sell
-108
Closed -$51K – 7711
2013
Q2 		$51K Buy
+108
New +$49K ﹤0.01% 6293

Other funds holding IDXG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Barclays's IDXG Position: Q2 2018 in Review

Barclays held its Interpace Biosciences, Inc. Common Stock (IDXG) position steady in Q2 2018 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7484.

Barclays first reported a position in IDXG in Q2 2013 and has held it in 1 quarter since. The position peaked at $51K in Q2 2013. 17 funds tracked by Wall St. Rank hold IDXG as of Q2 2018.

  • Barclays held 0 shares of Interpace Biosciences, Inc. Common Stock worth $0 as of Q2 2018.
  • Barclays left its Interpace Biosciences, Inc. Common Stock share count unchanged in Q2 2018.
  • Interpace Biosciences, Inc. Common Stock made up ﹤0.01% of Barclays's portfolio in Q2 2018, its #7484 holding.
  • Barclays first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and has held it in 1 quarter since.
  • Barclays's Interpace Biosciences, Inc. Common Stock position peaked at $51K in Q2 2013.
  • 17 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q2 2018.

Based on Barclays's 13F filing for Q2 2018, filed 14 Aug 2018.